Panacea Biotech Secures Major UNICEF Vaccine Order Boost, Stock in Focus

• Panacea Biotech's UNICEF contract for Easyfive-TT (pentavalent vaccine) updated for 2023-2027.
• Contract value for 2026 increased by $2.55 million to $16.8 million; 2027 by $2.70 million to $15.18 million.
• New $3.68 million order for 2027 received, enhancing future visibility.
• Company previously secured a long-term agreement with UNICEF for bOPV polio vaccines (2026-2030).
• Panacea Biotech specializes in WHO pre-qualified vaccines, pharma formulations, and biologics.

Why It Matters: Panacea Biotech strengthens its order book with increased UNICEF vaccine contract values and new orders.